

Business Operations
Ofelia San Pedro, Deputy Superintendent

SUBJECT: REQUEST FOR AUTHORIZATION TO AWARD REQUEST FOR PROPOSALS (RFP) # 088-FF10, BLOODBORNE PATHOGEN TRAINING AND HEPATITIS B VACCINATION PROGRAM AND AUTHORIZE THE PURCHASE OF VACCINATION SERUM THROUGH GLAXOSMITHKLINE'S PUBLIC CUSTOMER RATES

COMMITTEE: INNOVATION, EFFICIENCY & GOVERNMENTAL RELATIONS

The Occupational Safety and Health Administration (OSHA) promulgated the bloodborne program standard under the OSHA Act of 1970.29 U.S.C. 655, to eliminate or minimize occupational exposure to bloodborne pathogens. The standard became effective on March 6, 1992, for the private sector, and was adopted by the Florida Department of Labor and Security on January 27, 1993. The Miami-Dade County Public Schools Exposure Control Plan became effective on January 20, 1994. The Office of Risk and Benefits Management assumed responsibility for the program in December 2004.

The purpose of the plan is to eliminate or minimize exposure to bloodborne pathogens by utilizing a combination of training, engineering controls, work practice controls, personnel protective equipment, and to offer Hepatitis B vaccinations to identified employees.

The School Board currently utilizes six (6) in-house trainers consisting of retired administrators, to provide bloodborne hepatitis training utilizing a combination of printed material (in both Spanish and English), PowerPoint presentations and interactive material. During the 2004-2005 school year, trainers traveled to school sites and conducted 129 training sessions.

In addition to the trainers, the current program involves the district contracting with an outside vendor who attends these training sessions and provides Hepatitis B vaccinations to employees. In addition, employees may obtain vaccinations at the vendor's locations.

The vaccination serum is purchased through a separate vendor contract with GlaxoSmithKline. In the past the district purchased the serum through the State of Florida contract, however, the district has now been qualified as "Public Customer" and as such is entitled to discounted rates. The current rate for the Hepatitis B Vaccine is \$24.75 per dose.

**REVISED²
E-67**

At the March 15, 2006 Board Meeting the Board authorized staff to issue Request For Proposals (RFP) # 088-FF10 to determine if the district should contract with a third party vendor for part or all of the referenced services which make up the district's Bloodborne Pathogens Program.

Request for Proposals were sent to various vendors as well as being placed on the district's website, through the Office of Procurement Management. There are three main components to the RFP, the first component consists of providing the serum for the vaccinations, the second component is providing the training and the third component is providing the vaccinations.

Only one vendor responded to a portion of the RFP. Global MRO the current vendor which provides the vaccinations responded. Staff contacted the vendors who did not respond to the RFP to inquire as to why they did not respond. The majority of the vendors indicated that they did not have the expertise in all of the areas the RFP requested.

Global MRO response to RFP #088-FF10 provided a rate to perform the hepatitis vaccinations at \$12 per vaccination and \$20 per follow-up titer test. The existing rates are as follows: \$10 per vaccination \$18 per follow-up titer test. These rates will become effective October 1, 2006 through September 30, 2009.

Staff will continue to search for alternatives to the present format of utilizing retired administrators to provide education. To continue the current program, staff is recommending that the contract for vaccinations be awarded to Global MRO at the proposed rate of \$12/vaccinations and \$20 for follow-up titer tests and that the Board continues to purchase the serum through the GlaxoSmithKline contract the latest published "Public Customer" rates, which is currently 24.75 per dose.

RECOMMENDED: That The School Board of Miami-Dade County, Florida:

1. award Global MRO the administration of the Hepatitis B Vaccinations and Titer Tests for a three year term effective October 1, 2006 through September 30, 2009 at a rate of \$12 per vaccination and \$20 per follow-up titer test, pursuant to the provisions contained within RFP #088-FF10; and
2. authorize the continued purchase of The Hepatitis B vaccination from GlaxoSmithKline at the latest published current "Public Customer" rate which is currently \$24.75 per dose, for a three year term effective October 1, 2006 through September 30, 2009.

OSP:sbcc